Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Jost, Edgar  [Clear All Filters]
Journal Article
Tilmont R, Yakoub-Agha I, Eikema D-J, Zinger N, Haenel M, Schaap N, Arroyo CHerrera, Schuermans C, Besemer B, Engelhardt M, et al. Carfilzomib, lenalidomide and dexamethasone followed by a second ASCT is an effective strategy in first relapse multiple myeloma: a study on behalf of the Chronic malignancies working party of the EBMT. Bone Marrow Transplant. 2023.
de Vries ISNaarmann, Sackmann Y, Klein F, Ostareck-Lederer A, Ostareck DH, Jost E, Ehninger G, Brümmendorf TH, Marx G, Röllig C, et al. Characterization of acute myeloid leukemia with del(9q) - Impact of the genes in the minimally deleted region. Leuk Res. 2018;76:15-23.
Schwab B, Rudolph A, Jost E, Klinge U. Collaborative Network of Predictive Markers Complicates Formation of Prognostic Groups in Patients with Advanced Lung Cancer. Anticancer Res. 2014;34(6):2745-2754.
Bocova L, Hubens W, Engel C, Koschmieder S, Jost E, Wagner W. Correction: Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis. Clin Epigenetics. 2023;15(1):117.
Jost E, Herwartz R, Hoß M, Vankann L, Fuchs R. Cup-like blasts in acute myeloid leukemia. Am J Hematol. 2015.
Rolles B, Meyer R, Begemann M, Elbracht M, Jost E, Stelljes M, Kurth I, Brümmendorf TH, Silling G. DDX41 germline variants causing donor cell leukemia indicate a need for further genetic workup in the context of hematopoietic stem cell transplantation. Blood Cancer J. 2023;13(1):73.
Logan GE, Mor-Vaknin N, Braunschweig T, Jost E, Schmidt PVerena, Markovitz DM, Mills KI, Kappes F, Percy MJ. DEK oncogene expression during normal hematopoiesis and in Acute Myeloid Leukemia (AML). Blood Cells Mol Dis. 2014.
Koschmieder S, Jost E, Cornelissen C, Müller T, Schulze-Hagen M, Bickenbach J, Marx G, Kleines M, Marx N, Brümmendorf TH, et al. Favorable COVID-19 course despite significant comorbidities in a ruxolitinib-treated patient with primary myelofibrosis. Eur J Haematol. 2020.
Crysandt M, Brings K, Beier F, Thiede C, Brümmendorf TH, Jost E. Germline predisposition to myeloid malignancies appearing in adulthood. Expert Rev Hematol. 2018.
Crysandt M, Kramer M, Ehninger G, Bornhäuser M, Berdel WE, Serve H, Röllig C, Kaifie A, Jost E, Brümmendorf TH, et al. A high BMI is a risk factor in younger patients with de novo acute myelogenous leukemia. Eur J Haematol. 2015.
Enßle JC, Wolf S, Scheich S, Weber S, Kramer M, Ruhnke L, Schliemann C, Mikesch J-H, Krause S, Sauer T, et al. Impact of BMI on patient outcome in acute myeloid leukaemia patients receiving intensive induction therapy: a real-world registry experience. Br J Cancer. 2023.
Diener Y, Walenda T, Jost E, Brümmendorf TH, Bosio A, Wagner W, Bissels U. MicroRNA expression profiles of serum from patients before and after chemotherapy. Genom Data. 2015;6:125-7.
Walenda T, Diener Y, Jost E, Morin-Kensicki E, Goecke TW, Bosio A, Rath B, Brümmendorf TH, Bissels U, Wagner W. MicroRNAs and Metabolites in Serum Change after Chemotherapy: Impact on Hematopoietic Stem and Progenitor Cells. PLoS One. 2015;10(5):e0128231.
Bonifacius A, Lamottke B, Tischer-Zimmermann S, Schultze-Florey R, Goudeva L, Heuft H-G, Arseniev L, Beier R, Beutel G, Cario G, et al. Patient-tailored adoptive immunotherapy with EBV-specific T cells from related and unrelated donors. J Clin Invest. 2023.
Bocova L, Hubens W, Engel C, Koschmieder S, Jost E, Wagner W. Quantification of hematopoietic stem and progenitor cells by targeted DNA methylation analysis. Clin Epigenetics. 2023;15(1):105.
Stelljes M, Middeke JMoritz, Bug G, Wagner-Drouet E-M, Müller LP, Schmid C, Krause SW, Bethge W, Jost E, Platzbecker U, et al. Remission induction versus immediate allogeneic haematopoietic stem cell transplantation for patients with relapsed or poor responsive acute myeloid leukaemia (ASAP): a randomised, open-label, phase 3, non-inferiority trial. Lancet Haematol. 2024.
Crysandt M, Soysal H, Jennes E, Holtick U, Mrotzek M, Rehnelt S, Holderried TAW, Wessiepe M, Kunter U, Wilop S, et al. Selective ABO immunoadsorption in hematopoietic stem cell transplantation with major ABO incompatibility. Eur J Haematol. 2021.